Understanding how intravenous acyclovir works in children with cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the pharmacokinetics of intravenous acyclovir in pediatric patients with hematological malignancies or those undergoing hematopoietic stem cell transplantation. It aims to analyze how the drug behaves in the body, particularly in children, who may experience significant variability in drug metabolism. By monitoring drug levels and optimizing treatment protocols, the study seeks to improve outcomes for children at high risk of herpesvirus infections. The research is crucial for tailoring acyclovir therapy to enhance its effectiveness and safety in vulnerable pediatric populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with Hematological malignancies
* HSCT recipients who require ACV prophylaxis or treatment for HSV-VZV infection or
* Children undergoing high-intensity antineoplastic chemotherapy who need ACV treatment.
* Intravenous or oral ACV dosing
* Active/available a therapeutic drug monitoring (TDM) protocol for ACV
* Informed consent signed by patient's parents

Exclusion Criteria:

* lack of signed informed consent
* lack of TDM for ACV
* unavailable patient's demographic characteristics

Where it's running

• IRCCS Burlo Garofolo, Bone Marrow Transplant Unit, Institute for Maternal and Child Health
  Trieste, Ts, Italy Recruiting

Study contacts

• Principal investigator: Natalia Maximova, MD — IRCCS Burlo Garofolo
• Study coordinator: Natalia Maximova, MD
• Email: natalia-maximova@burlo.trieste.it
• Phone: 040 378 5111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing high and standard dose influenza vaccines in pediatric organ transplant recipients

  This study is testing whether a higher dose of the flu vaccine works better and is safe for kids aged 3 to 17 who have recently received an organ transplant.

  Recruiting at 11 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Stanford, California and 10 other locations · NCT05947071

• Monitoring molecular changes after kidney transplantation

  This study is testing if checking blood and tissue samples can help doctors spot problems early and improve outcomes for people who have received a kidney transplant.

  Recruiting Odense University Hospital · Odense, DK · NCT01515605

• Bridging psychosocial care after cancer treatment

  This study tests a routine digital distress screen plus a psycho-oncology navigation call to help cancer survivors access support after completing treatment.

  Recruiting University Hospital, Basel, Switzerland · Basel · NCT07672314

• Initial psycho-oncological contact for adults with cancer

  This study tests whether an initial psycho-oncological consultation helps reduce anxiety and depression and improve quality of life for adults with cancer.

  Recruiting Lindenhofgruppe AG · Basel and 4 other locations · NCT07544446

• Online psychoeducation to improve well-being after breast cancer

  This trial tests whether a 6-week online psychoeducation program can help women who finished breast cancer treatment at least a year ago feel better psychologically and improve their quality of life.

  Recruiting Uskudar University · Istanbul · NCT07284030

• Music therapy to reduce anxiety in cancer patients during MRI scans

  This study tests if music therapy can help cancer patients feel less anxious and more relaxed during MRI scans compared to standard care.

  Recruiting Guangzhou Concord Cancer Center · Guangzhou, Guangdong · NCT06282887

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.